Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Stein

Showing results (21-30 of 400) with videos related to

Pageof 40
Sort By:
The New England Journal of Medicine|May 21, 2004
New drugs for rheumatoid arthritisNancy J Olsen, C Michael Stein
The New England Journal of Medicine|October 1, 2010
The ethics of placebo in studies with fracture end points in osteoporosisC Michael Stein, Wayne A Ray
The Journal of Rheumatology|October 3, 2014
Is visceral fat the missing link in the relationship between inflammation and insulin resistance in RA?Michelle J Ormseth, C Michael Stein
The New England Journal of Medicine|May 16, 2008
The aprotinin story--is BART the final chapter?Wayne A Ray, C Michael Stein
Clinical Pharmacology and Therapeutics|July 4, 2006
Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulantsUte I Schwarz, C Michael Stein
The Israel Medical Association Journal : IMAJ|June 4, 2002
Earthquake disasters--lessons to be learnedKobi Peleg, Haim Reuveni, Michael Stein
Circulation|April 29, 2009
Clopidogrel and the concept of high-risk pharmacokineticsDan M Roden, C Michael Stein
The Journal of Trauma|September 15, 2010
Poorer outcomes for mass casualty events victims: is it evidence based?Kobi Peleg, Michael Rozenfeld, Michael Stein
AIDS and Behavior|April 23, 2014
Willingness to use HIV pre-exposure prophylaxis among opiate usersMichael Stein, Portia Thurmond, Genie Bailey
Annals of Internal Medicine|January 5, 2002
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?Theodore Pincus, Tuulikki Sokka, C Michael Stein
Pageof 40

Showing results (21-30 of 400) with videos related to

Sort By:
Pageof 40
The New England Journal of Medicine|May 21, 2004
New drugs for rheumatoid arthritisNancy J Olsen, C Michael Stein
The New England Journal of Medicine|October 1, 2010
The ethics of placebo in studies with fracture end points in osteoporosisC Michael Stein, Wayne A Ray
The Journal of Rheumatology|October 3, 2014
Is visceral fat the missing link in the relationship between inflammation and insulin resistance in RA?Michelle J Ormseth, C Michael Stein
The New England Journal of Medicine|May 16, 2008
The aprotinin story--is BART the final chapter?Wayne A Ray, C Michael Stein
Clinical Pharmacology and Therapeutics|July 4, 2006
Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulantsUte I Schwarz, C Michael Stein
The Israel Medical Association Journal : IMAJ|June 4, 2002
Earthquake disasters--lessons to be learnedKobi Peleg, Haim Reuveni, Michael Stein
Circulation|April 29, 2009
Clopidogrel and the concept of high-risk pharmacokineticsDan M Roden, C Michael Stein
The Journal of Trauma|September 15, 2010
Poorer outcomes for mass casualty events victims: is it evidence based?Kobi Peleg, Michael Rozenfeld, Michael Stein
AIDS and Behavior|April 23, 2014
Willingness to use HIV pre-exposure prophylaxis among opiate usersMichael Stein, Portia Thurmond, Genie Bailey
Annals of Internal Medicine|January 5, 2002
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?Theodore Pincus, Tuulikki Sokka, C Michael Stein
Pageof 40